Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haematologica.org) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organization, and serves the scientific community with strict adherence to the principles of open access publishing (www.doaj.org). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature. While the role of ATO in remission re-induction is well established, the best consolidation strategy to be used in relapsed APL still remains controversial. In fact, because of the few patient numbers involved, no randomised studies are available which may definitely support a given consolidation (allo-HSCT, auto-SCT, further ATO or chemotherapy). This notwithstanding, most investigators would nowadays recommend to proceed to HSCT after re-induction of CRm 1,2 . However, the effect of prolonged ATO administration beyond consolidation, particularly for patients unfit to receive HSCT or as an alternative to the latter for patients with better prognosis (e.g. long duration of 1 st CR) has not been widely investigated. We report here on the outcome of 9 patients with relapsed APL, who received prolonged therapy with an ATO plus ATRA combination 3 . Nine patients with relapsed APL were treated with prolonged ATRA and ATO at the Department of Cellular Biotechnologies and Hematology of the University La Sapienza (6 cases) and at the Department of Biopathology of the University Tor Vergata (3 cases) of Rome. The main clinico-biological features and treatment outcome of the 9 patients are shown in Table 1 .
UPN 5 and UPN 6 have been reported previously 4, 5 . At time of ATO/ATRA initiation, 7
patients were in 1st molecular relapse, whereas UPN 8 and 9 were in 2nd haematological and 2nd molecular relapse, respectively. The median time of molecular or hematologic 1st
CR duration was 1.9 years (range 1 CR. Relapses were in that study hematological in 12 cases and molecular in 1 case. All patients were treated with chemotherapy and after consolidation all achieved CRm: 10/13 patients (77%) were alive and well after a median follow-up of 25 months from 2nd CR 8 .
We report here similar results with an ATO-based salvage therapy, with 88% of patients remaining in prolonged CRm without transplant procedures. Further studies in larger series are warranted to better establish whether autologous and allogeneic HSCT might be avoided in patients with late relapse APL receiving a prolonged ATO plus ATRA therapy. 
